Abstract
Sacituzumab govitecan is an antibody-drug conjugate comprised of an active metabolite of irinotecan SN-38 bound to a hu-ma-ni-zed monoclonal antibody targeting trophoblastic cell-surface antigen 2 (Trop-2). Trop-2 is highly expressed on the surface of triple-negative breast cancer (TNBC) cells, making it an attractive target.
Sacituzumab govitecan has promising survival benefits in patients with previously treated metastatic TNBC based on data from the ASCENT trial. Common adverse effects were neutropenia, diarrhea, and nausea; however, these effects were manageable with supportive care.